Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

about

Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

P2860

Q33411001-AB33C564-E8ED-4565-9CFB-5D0BE33359A3 Q36112023-C2BBDEB2-E5C4-4F38-B14D-F1057136234C

P2860

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

Item

http://www.wikidata.org/entity/Q42089287

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

@en

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

@nl

type

Item

label

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

@en

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

@nl

prefLabel

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

@en

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

@nl

P1476

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

@en

P2093

Beom Joon Kim

http://www.w3.org/2001/XMLSchema#string

Dong Ha Kim

http://www.w3.org/2001/XMLSchema#string

Hye In Lee

http://www.w3.org/2001/XMLSchema#string

In Pyeong Son

http://www.w3.org/2001/XMLSchema#string

Jin Woong Lee

http://www.w3.org/2001/XMLSchema#string

Myeung Nam Kim

http://www.w3.org/2001/XMLSchema#string

P2860

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Mucocutaneous reactions to chemotherapy.

Sorafenib for the treatment of advanced renal cell carcinoma.

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

P304

119-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.5021/AD.2011.23.1.119

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51476120

http://www.w3.org/2001/XMLSchema#string

P698

21738381

http://www.w3.org/2001/XMLSchema#string

P932

3119991

http://www.w3.org/2001/XMLSchema#string

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

about

P2860

P2860

Sorafenib (Nexavar®, BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932